Hematology Featured Articles
-
A Chief Scientific Officer’s Opinion On Clinical Outsourcing
4/16/2013
Dr. Kenneth Burhop is the chief scientific officer of Sangart Inc., a biopharmaceutical company that engages in the research, development, and commercialization of oxygen therapeutics. He joined Sangart in January 2011, after serving as the global scientific lead/CSO for Baxter Healthcare’s Medication Delivery division and VP of R&D for Baxter's Biopharmaceutical Technologies business, including the company’s second generation recombinant hemoglobin program. He has authored over forty publications, more than seventy abstracts, several book chapters, and has been invited to speak at various international meetings and symposia, and is a recognized international expert in the field of hemoglobin therapeutics. Burhop shares his opinions on clinical outsourcing.
-
Quantifying The Potential Value Of Orphan Drugs
10/31/2012
An explosive growth to orphan drugs has launched due to government incentives, longer exclusivity rights, and advantageous pricing structures and analysts suggest the CAGR of orphan drugs will outperform non-orphan drugs due to several factors.
-
The Emergence Of A Hybrid Laboratory Testing Model In Pharmaceutical Clinical Trials
4/24/2012
Thought leaders aware of technology and standard medical practices, foresee the emergence of a hybrid laboratory testing model for clinical trials. Clinical laboratories used by physicians and hospitals were compelled to innovate and adapt to the demands of managed care to do more with less while doing it faster.